# WIA-AUG-010: Artificial Organ Specification v1.0

> **Standard ID:** WIA-AUG-010
> **Version:** 1.0.0
> **Published:** 2025-12-27
> **Status:** Active
> **Authors:** WIA Human Augmentation Working Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Organ Classification Taxonomy](#2-organ-classification-taxonomy)
3. [Technology Type Framework](#3-technology-type-framework)
4. [Biocompatibility Assessment](#4-biocompatibility-assessment)
5. [Function Monitoring System](#5-function-monitoring-system)
6. [Rejection Detection Protocol](#6-rejection-detection-protocol)
7. [Performance Optimization](#7-performance-optimization)
8. [Power and Energy Systems](#8-power-and-energy-systems)
9. [Maintenance and Service Scheduling](#9-maintenance-and-service-scheduling)
10. [Failsafe and Emergency Protocols](#10-failsafe-and-emergency-protocols)
11. [Interoperability Standards](#11-interoperability-standards)
12. [Implementation Guidelines](#12-implementation-guidelines)
13. [References](#13-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines a comprehensive framework for artificial organ technologies, providing standardized classification systems, biocompatibility protocols, function monitoring, rejection detection, and interoperability guidelines for artificial organ devices and systems.

### 1.2 Scope

The standard covers:
- Taxonomy and classification of artificial organ types
- Technology category frameworks (mechanical, bioartificial, bioprinted, xenotransplant)
- Biocompatibility assessment protocols
- Real-time function monitoring systems
- Rejection detection and early warning
- Performance optimization algorithms
- Power and energy system requirements
- Maintenance scheduling and predictive service
- Emergency failsafe mechanisms
- Interoperability and data exchange standards

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - Artificial organ technology should restore and enhance organ function while maintaining patient safety, quality of life, and equitable access. This specification ensures that artificial organs are developed with standardized frameworks that promote biocompatibility, reliability, and ethical deployment.

### 1.4 Terminology

- **Artificial Organ**: Device or biological construct that replaces or augments natural organ function
- **Biocompatibility**: Degree of compatibility between artificial organ and host tissue
- **Rejection**: Immune system response against artificial organ or its components
- **Function Metrics**: Quantifiable measurements of organ performance
- **Failsafe**: Backup system activated during primary system failure
- **Xenotransplant**: Transplantation of cells, tissues, or organs from non-human species

---

## 2. Organ Classification Taxonomy

### 2.1 Primary Organ Types

Artificial organs are classified into eight primary types:

| Type | Code | Primary Function | Critical Metrics |
|------|------|------------------|------------------|
| Heart | HEART | Cardiac output, circulation | Flow rate, pressure, rhythm |
| Kidney | KIDNEY | Filtration, fluid balance | GFR, electrolytes, waste removal |
| Liver | LIVER | Metabolism, detoxification | Enzyme synthesis, waste processing |
| Lung | LUNG | Gas exchange | O2/CO2 transfer, ventilation |
| Pancreas | PANCREAS | Endocrine, exocrine | Insulin, glucose control, enzymes |
| Bladder | BLADDER | Urinary storage | Capacity, pressure, continence |
| Intestine | INTESTINE | Digestion, absorption | Nutrient uptake, motility |
| Skin | SKIN | Barrier, sensation | Coverage, healing, sensory function |

### 2.2 Classification Algorithm

```typescript
interface OrganInput {
  primaryFunction: OrganType;
  technologyApproach: TechnologyType;
  targetPerformance: number; // % of natural organ
  invasiveness: number; // 1-10
  reversibility: boolean;
}

function classifyOrgan(input: OrganInput): OrganClassification {
  const type = input.primaryFunction;
  const technology = input.technologyApproach;
  const performanceLevel = determinePerformanceLevel(input.targetPerformance);
  const safetyClass = calculateSafetyClass(input.invasiveness, technology);

  return {
    type,
    technology,
    performanceLevel,
    safetyClass,
    reversible: input.reversibility
  };
}
```

### 2.3 Organ-Specific Requirements

#### 2.3.1 Heart (Cardiac)
- **Flow Rate**: 4-6 L/min at rest, 20-25 L/min peak
- **Pressure**: Systolic 120 mmHg, Diastolic 80 mmHg
- **Rhythm**: 60-100 bpm, regular
- **Efficiency**: >75% mechanical efficiency
- **Durability**: >5 years continuous operation

#### 2.3.2 Kidney (Renal)
- **GFR**: >90 ml/min/1.73m² optimal
- **Filtration**: Creatinine clearance >80 ml/min
- **Electrolyte Balance**: Na⁺, K⁺, Ca²⁺, PO₄³⁻ regulation
- **Waste Removal**: Urea, creatinine, toxins
- **Durability**: >3 years with maintenance

#### 2.3.3 Liver (Hepatic)
- **Detoxification**: Ammonia → urea conversion
- **Synthesis**: Albumin, clotting factors, glucose
- **Metabolism**: Drug metabolism, lipid processing
- **Storage**: Glycogen, vitamins, minerals
- **Regeneration**: Self-repair capability (bioartificial)

#### 2.3.4 Lung (Pulmonary)
- **Gas Exchange**: O₂ uptake >250 ml/min, CO₂ removal >200 ml/min
- **Ventilation**: Tidal volume 500 ml, RR 12-20/min
- **Compliance**: Adequate chest wall interaction
- **Resistance**: Minimal airway resistance
- **Durability**: >2 years continuous operation

#### 2.3.5 Pancreas (Endocrine/Exocrine)
- **Insulin Production**: Glucose-responsive 40-50 units/day
- **Glucose Control**: Maintain 70-140 mg/dL
- **Enzyme Production**: Amylase, lipase, proteases
- **Response Time**: <15 minutes to glucose changes
- **Biocompatibility**: High, minimal immune response

#### 2.3.6 Bladder (Urinary)
- **Capacity**: 300-500 ml
- **Continence**: >95% leak-free
- **Pressure Management**: <40 cmH₂O at capacity
- **Sensation**: Fullness awareness (if neural integrated)
- **Durability**: >5 years

#### 2.3.7 Intestine (Digestive)
- **Absorption**: >70% nutrient uptake
- **Motility**: Peristaltic movement
- **Barrier Function**: Prevent bacterial translocation
- **Surface Area**: Adequate villi/microvilli
- **Durability**: >3 years with maintenance

#### 2.3.8 Skin (Integumentary)
- **Coverage**: Complete wound closure
- **Barrier Function**: Prevent infection, water loss
- **Sensation**: Touch, temperature, pain (if integrated)
- **Appearance**: Cosmetically acceptable
- **Healing**: Integration with surrounding tissue

---

## 3. Technology Type Framework

### 3.1 Technology Categories

Five primary technology approaches for artificial organs:

| Type | Code | Mechanism | Examples | Advantages | Challenges |
|------|------|-----------|----------|------------|------------|
| Mechanical | MECH | Electromechanical devices | Total artificial heart, dialysis | Reliable, durable | Biocompatibility, power |
| Bioartificial | BIOART | Living cells + scaffold | BAL, bioartificial kidney | Natural function | Cell viability, scaling |
| 3D Bioprinted | BIOPRINT | Printed tissue constructs | Skin, bladder, vascular | Patient-specific | Complexity, vascularization |
| Xenotransplant | XENO | Modified animal organs | Pig heart, kidney | Availability, complete | Rejection, disease risk |
| Hybrid | HYBRID | Combined approaches | Bio-mechanical devices | Optimized performance | Integration complexity |

### 3.2 Technology Selection Criteria

```
Technology Score = (Function_Match × 0.30) +
                   (Biocompatibility × 0.25) +
                   (Durability × 0.20) +
                   (Availability × 0.15) +
                   (Cost_Effectiveness × 0.10)

where each factor is scored 0-1

Recommendations:
  Score ≥ 0.80: Highly Recommended
  Score 0.60-0.79: Recommended with conditions
  Score 0.40-0.59: Alternative approaches suggested
  Score < 0.40: Not recommended
```

### 3.3 Mechanical Systems

#### 3.3.1 Design Requirements
- **Materials**: Titanium, medical-grade polymers, ceramics
- **Surface Treatment**: Anti-thrombogenic coatings
- **Pumping Mechanism**: Continuous flow or pulsatile
- **Wear Resistance**: >5 million cycles without degradation
- **Noise Level**: <40 dB

#### 3.3.2 Control Systems
- **Sensors**: Pressure, flow, temperature
- **Feedback**: Real-time performance adjustment
- **Safety Limits**: Automatic shutoff on fault detection
- **Power Management**: Battery backup, low-power modes

### 3.4 Bioartificial Systems

#### 3.4.1 Cell Requirements
- **Cell Type**: Primary cells, stem cell-derived, immortalized lines
- **Viability**: >90% at implantation, >70% at 1 year
- **Function**: Organ-specific metabolic activity
- **Immunoisolation**: Encapsulation or genetic modification
- **Nutrient Supply**: Vascularization or perfusion system

#### 3.4.2 Scaffold Requirements
- **Material**: Biodegradable (PCL, PLGA) or permanent (hydrogels)
- **Architecture**: Porous, 3D structure mimicking natural ECM
- **Mechanical Strength**: Adequate for organ function
- **Biocompatibility**: ISO 10993 compliant
- **Degradation**: Controlled rate matching tissue ingrowth

### 3.5 3D Bioprinted Systems

#### 3.5.1 Bioprinting Requirements
- **Resolution**: 50-200 μm for cell placement
- **Bioink**: Cell-laden hydrogels with >85% cell viability
- **Vascularization**: Integrated blood vessel network
- **Maturation**: In vitro culture before implantation
- **Quality Control**: Imaging, function testing, sterility

#### 3.5.2 Tissue Engineering
- **Cell Density**: Organ-appropriate cell concentration
- **ECM Components**: Collagen, fibronectin, laminin
- **Growth Factors**: VEGF, bFGF for vascularization
- **Mechanical Stimulation**: Bioreactor conditioning
- **Integration**: Host tissue infiltration

### 3.6 Xenotransplant Systems

#### 3.6.1 Genetic Modification
- **Human Transgenes**: HLA, CD55, CD59 for immune protection
- **Knockout Genes**: α-Gal, CMAH, Neu5Gc for antigen reduction
- **PERV Inactivation**: Eliminate porcine endogenous retrovirus
- **Quality Assurance**: Genetic stability verification

#### 3.6.2 Immunosuppression
- **Protocol**: Multi-drug regimen (calcineurin inhibitors, corticosteroids)
- **Monitoring**: Drug levels, immune markers
- **Infection Prevention**: Prophylactic antimicrobials
- **Long-term**: Tolerance induction strategies

---

## 4. Biocompatibility Assessment

### 4.1 Biocompatibility Framework

```
Biocompatibility Score = (Tissue_Integration × 0.30) +
                         (Immune_Response × 0.25) +
                         (Material_Safety × 0.25) +
                         (Functional_Stability × 0.20)

where:
- Tissue_Integration: Capsule thickness, vascularization (0-1)
- Immune_Response: Inflammation markers, cell infiltration (0-1, 1=minimal)
- Material_Safety: Toxicity, degradation products (0-1)
- Functional_Stability: Performance over time (0-1)
```

### 4.2 Tissue Integration Assessment

```typescript
interface TissueIntegration {
  capsuleThickness: number;        // mm (thinner is better)
  vascularization: number;         // vessels/mm²
  cellInfiltration: number;        // cells/mm² (appropriate type)
  fibrosis: number;                // 0-4 score (0=none)
  adhesions: number;               // 0-4 score (0=none)
}

function assessTissueIntegration(data: TissueIntegration): number {
  const capsuleScore = capsuleNormalize(data.capsuleThickness); // <1mm = good
  const vascScore = vascularizationNormalize(data.vascularization);
  const fibrosisScore = 1 - (data.fibrosis / 4);
  const adhesionScore = 1 - (data.adhesions / 4);

  return (capsuleScore + vascScore + fibrosisScore + adhesionScore) / 4;
}
```

### 4.3 Immune Response Monitoring

#### 4.3.1 Inflammation Markers
- **CRP (C-Reactive Protein)**: <10 mg/L normal, 10-100 moderate, >100 high
- **ESR (Erythrocyte Sedimentation Rate)**: <20 mm/h normal
- **WBC (White Blood Cell Count)**: 4,000-11,000/μL normal
- **Cytokines**: IL-6, TNF-α, IL-1β levels
- **Complement**: C3, C4 activation

#### 4.3.2 Antibody Surveillance
- **Anti-HLA Antibodies**: Donor-specific antibodies (DSA)
- **Panel Reactive Antibodies (PRA)**: % reactivity
- **IgG/IgM**: Immunoglobulin levels
- **Crossmatch**: T-cell, B-cell crossmatch tests
- **Monitoring Frequency**: Weekly (month 1), monthly (months 2-12), quarterly thereafter

### 4.4 Material Safety Testing

#### 4.4.1 ISO 10993 Compliance
- **Cytotoxicity**: In vitro cell viability >70%
- **Sensitization**: Guinea pig maximization test
- **Irritation**: Rabbit dermal/ocular testing
- **Systemic Toxicity**: Acute and subchronic studies
- **Genotoxicity**: Ames test, chromosomal aberration
- **Implantation**: Subcutaneous implant studies (4-52 weeks)
- **Hemocompatibility**: Hemolysis, thrombogenicity, complement

#### 4.4.2 Degradation Product Analysis
- **Leachables**: Chemical analysis of released substances
- **Particulates**: Size, composition, toxicity
- **Metal Ions**: Titanium, cobalt, chromium levels (if applicable)
- **Polymer Breakdown**: Monomer, oligomer detection
- **Biological Products**: Cell debris, proteins

---

## 5. Function Monitoring System

### 5.1 Real-Time Monitoring Framework

```typescript
interface FunctionMetrics {
  organId: string;
  timestamp: Date;

  output: {
    value: number;              // Organ-specific units
    unit: string;               // L/min, ml/min, units/day
    target: number;             // Expected value
    percentOfTarget: number;    // %
  };

  efficiency: {
    value: number;              // 0-1
    energyInput: number;        // Watts or metabolic equivalent
    usefulOutput: number;       // Functional units
  };

  biomarkers: {
    bloodChemistry: Record<string, number>;
    metabolicIndicators: Record<string, number>;
    organSpecific: Record<string, number>;
  };

  physiology: {
    temperature: number;        // °C
    pressure: number;           // mmHg or cmH₂O
    flow: number;              // ml/min
    resistance: number;        // dynes·s/cm⁵ or equivalent
  };
}
```

### 5.2 Organ-Specific Monitoring

#### 5.2.1 Heart Monitoring
```
Primary Metrics:
- Cardiac Output: 4-6 L/min (rest), up to 25 L/min (peak)
- Ejection Fraction: >55% (if pulsatile)
- Stroke Volume: 60-100 ml/beat
- Heart Rate: 60-100 bpm (if rhythm control)
- Pressure: Systolic 120±20, Diastolic 80±10 mmHg

Secondary Metrics:
- Power Output: 1-2 Watts (rest)
- Efficiency: >75%
- Temperature: 36-38°C
- Thrombosis Markers: D-dimer, platelet count
```

#### 5.2.2 Kidney Monitoring
```
Primary Metrics:
- GFR: >90 ml/min/1.73m² (optimal)
- Urine Output: 800-2000 ml/day
- Creatinine Clearance: >80 ml/min
- BUN: 7-20 mg/dL
- Electrolytes: Na⁺ 135-145, K⁺ 3.5-5.0 mEq/L

Secondary Metrics:
- Fluid Balance: Input vs. output
- Acid-Base: pH 7.35-7.45
- Phosphate Removal: Adequate control
- Albumin Loss: Minimal proteinuria
```

#### 5.2.3 Liver Monitoring
```
Primary Metrics:
- ALT/AST: <40 U/L (normal function)
- Bilirubin: 0.3-1.2 mg/dL
- Albumin: 3.5-5.0 g/dL
- PT/INR: 0.9-1.1 (normal coagulation)
- Ammonia: <50 μg/dL

Secondary Metrics:
- Glucose Production: Maintain 70-140 mg/dL
- Lipid Metabolism: Cholesterol, triglycerides
- Drug Clearance: Appropriate half-lives
- Synthetic Function: Clotting factors
```

#### 5.2.4 Lung Monitoring
```
Primary Metrics:
- O₂ Saturation: >95%
- PaO₂: >80 mmHg
- PaCO₂: 35-45 mmHg
- Tidal Volume: 500 ml (6-8 ml/kg)
- Respiratory Rate: 12-20/min

Secondary Metrics:
- Compliance: >100 ml/cmH₂O
- Resistance: <2.5 cmH₂O/L/s
- Dead Space: <30% of tidal volume
- Shunt Fraction: <5%
```

### 5.3 Alert Thresholds

```
Critical Alerts (Immediate Response):
- Output <50% of target
- Efficiency <60%
- Temperature >39°C or <35°C
- Pressure outside 50-200% of normal
- Biomarker deviation >3 SD from baseline

Warning Alerts (Monitor Closely):
- Output 50-70% of target
- Efficiency 60-75%
- Temperature 38-39°C or 35-36°C
- Pressure outside 75-150% of normal
- Biomarker deviation 2-3 SD from baseline

Information (Trending):
- Output 70-90% of target
- Efficiency 75-85%
- Minor biomarker fluctuations
- Performance degradation trends
```

---

## 6. Rejection Detection Protocol

### 6.1 Rejection Risk Assessment

```
Rejection Risk Score = (Immune_Markers × 0.35) +
                       (Performance_Degradation × 0.30) +
                       (Inflammation_Indicators × 0.20) +
                       (Antibody_Levels × 0.15)

where each factor is scored 0-1 (1 = high risk)

Risk Levels:
  Score > 0.70: High Risk - Immediate intervention
  Score 0.40-0.70: Moderate Risk - Increase monitoring, adjust immunosuppression
  Score < 0.40: Low Risk - Continue standard monitoring
```

### 6.2 Immune Marker Surveillance

```typescript
interface ImmuneMarkers {
  CRP: number;                  // mg/L
  ESR: number;                  // mm/h
  WBC: number;                  // cells/μL
  lymphocytes: number;          // %
  cytokines: {
    IL6: number;                // pg/ml
    TNFalpha: number;           // pg/ml
    IL1beta: number;            // pg/ml
    IFNgamma: number;           // pg/ml
  };
  complement: {
    C3: number;                 // mg/dL
    C4: number;                 // mg/dL
    CH50: number;               // U/ml
  };
}

function assessImmuneMarkers(markers: ImmuneMarkers): number {
  let score = 0;

  // CRP scoring
  if (markers.CRP > 100) score += 0.35;
  else if (markers.CRP > 50) score += 0.20;
  else if (markers.CRP > 10) score += 0.10;

  // ESR scoring
  if (markers.ESR > 50) score += 0.15;
  else if (markers.ESR > 30) score += 0.08;

  // Cytokine elevation
  const cytoScore = calculateCytokineScore(markers.cytokines);
  score += cytoScore * 0.30;

  // Complement activation
  const compScore = calculateComplementScore(markers.complement);
  score += compScore * 0.20;

  return Math.min(score, 1.0);
}
```

### 6.3 Performance Degradation Monitoring

```typescript
interface PerformanceTrend {
  currentOutput: number;
  baselineOutput: number;
  trend7days: number;          // % change
  trend30days: number;         // % change
  variability: number;         // coefficient of variation
  efficiency: number;          // current vs. baseline
}

function assessPerformanceDegradation(trend: PerformanceTrend): number {
  const outputRatio = trend.currentOutput / trend.baselineOutput;
  const trendScore = calculateTrendScore(trend.trend7days, trend.trend30days);
  const variabilityScore = trend.variability; // Higher = worse
  const efficiencyScore = 1 - trend.efficiency;

  return (
    (1 - outputRatio) * 0.40 +
    trendScore * 0.30 +
    variabilityScore * 0.20 +
    efficiencyScore * 0.10
  );
}
```

### 6.4 Antibody Level Monitoring

```
Antibody Testing Schedule:
- Week 1: Every 2-3 days
- Weeks 2-4: Weekly
- Months 2-6: Bi-weekly
- Months 7-12: Monthly
- Year 2+: Quarterly (or as indicated)

Tests:
1. Donor-Specific Antibodies (DSA)
   - Class I HLA (HLA-A, -B, -C)
   - Class II HLA (HLA-DR, -DQ, -DP)
   - MFI (Mean Fluorescence Intensity) >1000 = significant

2. Panel Reactive Antibodies (PRA)
   - % reactivity to panel
   - >80% = highly sensitized

3. Crossmatch Tests
   - T-cell crossmatch
   - B-cell crossmatch
   - Flow cytometry crossmatch
```

### 6.5 Rejection Response Protocol

```
High Risk Detection (Score > 0.70):
1. Immediate notification to medical team
2. Increase immunosuppression (per protocol)
3. Daily monitoring of all markers
4. Biopsy if indicated (for biological organs)
5. Consider rescue therapy (methylprednisolone, thymoglobulin)
6. Evaluate for infection vs. rejection

Moderate Risk (Score 0.40-0.70):
1. Alert medical team
2. Increase monitoring frequency (2x)
3. Review immunosuppression levels
4. Adjust medications if subtherapeutic
5. Screen for infection
6. Trend markers closely

Low Risk (Score < 0.40):
1. Continue standard monitoring
2. Maintain current immunosuppression
3. Routine follow-up
4. Patient education on warning signs
```

---

## 7. Performance Optimization

### 7.1 Adaptive Control Algorithms

```typescript
interface ControlParameters {
  targetOutput: number;
  currentOutput: number;
  energyInput: number;
  physiologicalDemand: number;

  controlMode: 'FIXED' | 'ADAPTIVE' | 'PREDICTIVE';

  constraints: {
    maxOutput: number;
    minOutput: number;
    maxPower: number;
    safetyLimits: SafetyLimits;
  };
}

class AdaptiveController {
  optimize(params: ControlParameters): ControlOutput {
    // PID control for output regulation
    const error = params.targetOutput - params.currentOutput;
    const pidOutput = this.pidController(error);

    // Feedforward based on physiological demand
    const demandCompensation = this.estimateDemand(params.physiologicalDemand);

    // Efficiency optimization
    const optimalOperatingPoint = this.findOptimalEfficiency(
      params.currentOutput,
      params.energyInput
    );

    // Combine control signals
    const controlSignal = this.combineSignals(
      pidOutput,
      demandCompensation,
      optimalOperatingPoint
    );

    // Apply constraints and safety limits
    return this.applyConstraints(controlSignal, params.constraints);
  }
}
```

### 7.2 Efficiency Optimization

```
Efficiency = (Useful_Output / Total_Energy_Input) × 100%

For Mechanical Heart:
Useful_Output = Cardiac Work = Pressure × Flow × Conversion_Factor
Total_Energy_Input = Electrical Power Consumption

Target: >75% efficiency

Optimization Strategies:
1. Variable Speed Control: Match RPM to demand
2. Pulsatile vs. Continuous: Select based on physiology
3. Power Management: Sleep modes during low demand
4. Thermal Management: Minimize heat generation
5. Wear Optimization: Reduce friction, extend life
```

### 7.3 Predictive Maintenance

```typescript
interface MaintenancePredictor {
  operatingHours: number;
  cycleCount: number;
  performanceHistory: PerformanceData[];
  wearIndicators: WearMetrics;

  predictNextService(): ServicePrediction {
    const hoursToService = this.calculateHoursToService();
    const cyclesToService = this.calculateCyclesToService();
    const performanceDegradation = this.trendAnalysis();
    const wearLevel = this.assessWear();

    return {
      estimatedServiceDate: new Date(Date.now() + hoursToService * 3600000),
      confidenceLevel: this.calculateConfidence(),
      recommendedActions: this.generateRecommendations(),
      urgency: this.determineUrgency(wearLevel, performanceDegradation)
    };
  }
}
```

---

## 8. Power and Energy Systems

### 8.1 Power System Types

| Type | Technology | Capacity | Duration | Recharge | Applications |
|------|-----------|----------|----------|----------|--------------|
| Battery | Li-ion, LiFePO₄ | 10-100 Wh | 8-24h | External, wireless | Hearts, pumps |
| TET | Transcutaneous Energy Transfer | Continuous | Unlimited | Wireless coil | Implanted devices |
| Biofuel | Glucose fuel cell | 1-10 mW | Continuous | Biological | Bioartificial |
| Hybrid | Battery + TET | 50-200 Wh | >24h | Multiple modes | Advanced systems |
| External | Direct connection | Unlimited | Continuous | N/A | Dialysis, ECMO |

### 8.2 Battery Requirements

```
Primary Battery:
- Capacity: 8-12 hours typical use
- Charge Time: <4 hours to 80%, <6 hours to 100%
- Cycle Life: >1000 full cycles
- Safety: Overcharge, overdischarge, temperature protection
- Indicators: LED, app, audible alerts

Backup Battery:
- Capacity: 30-60 minutes minimum
- Auto-Switchover: <1 second
- Alert: Immediate notification
- Hot-Swappable: Allow primary battery change

Power Management:
- Low Power Mode: Reduce non-critical functions
- Sleep Mode: Minimal power during rest
- Adaptive: Match power to physiological demand
```

### 8.3 Wireless Power Transfer

```
TET System Specifications:
- Frequency: 100-300 kHz typical
- Efficiency: >70% coil-to-coil
- Distance: 5-20 mm tissue penetration
- Power Delivery: 5-50 Watts
- Safety: Temperature monitoring, SAR limits
- Alignment: Magnetic coupling feedback

Design Requirements:
- External Coil: Wearable, comfortable
- Internal Coil: Biocompatible encapsulation
- Positioning: Stable anatomical location
- Interference: EMI shielding, filtering
```

### 8.4 Biofuel Cells

```
Glucose Fuel Cell:
- Mechanism: Glucose oxidation for power
- Power Output: 1-10 mW continuous
- Efficiency: 20-40% glucose to electrical
- Location: Bloodstream, interstitial fluid
- Electrodes: Biocompatible carbon, platinum
- Applications: Low-power sensors, pacing

Advantages:
- Continuous fuel source (glucose)
- No external charging
- Fully implantable
- Long-term stability

Challenges:
- Limited power output
- Biofouling of electrodes
- Glucose variability
- Safety (biocompatibility)
```

---

## 9. Maintenance and Service Scheduling

### 9.1 Maintenance Framework

```
Maintenance Types:
1. Preventive: Scheduled based on time/cycles
2. Predictive: Based on performance trends and wear
3. Corrective: In response to faults or degradation
4. Emergency: Immediate intervention for critical issues

Frequency:
- Daily: Self-check, battery status
- Weekly: Performance review, alert check
- Monthly: Comprehensive function test
- Quarterly: Clinical assessment, biomarkers
- Annually: Major inspection, component replacement if needed
```

### 9.2 Service Scheduling Algorithm

```typescript
interface ServiceSchedule {
  lastServiceDate: Date;
  operatingHours: number;
  cycleCount: number;
  performanceMetrics: PerformanceHistory;
  wearIndicators: WearAssessment;

  calculateNextService(): ServiceRecommendation {
    // Time-based component
    const timeSinceService = Date.now() - this.lastServiceDate.getTime();
    const timeScore = timeSinceService / (365 * 24 * 3600 * 1000); // Years

    // Usage-based component
    const hoursScore = this.operatingHours / this.expectedLifeHours;
    const cyclesScore = this.cycleCount / this.expectedLifeCycles;

    // Performance-based component
    const performanceScore = this.assessPerformanceDegradation();

    // Wear-based component
    const wearScore = this.assessWearLevel();

    // Combined score
    const serviceScore = Math.max(
      timeScore * 0.20,
      hoursScore * 0.25,
      cyclesScore * 0.25,
      performanceScore * 0.20,
      wearScore * 0.10
    );

    return {
      urgency: this.scoreToUrgency(serviceScore),
      recommendedDate: this.calculateDate(serviceScore),
      reason: this.determineReason(serviceScore),
      estimatedDowntime: this.estimateDowntime()
    };
  }
}
```

### 9.3 Component Replacement Guidelines

```
Mechanical Heart:
- Bearings: Every 3-5 years or 50M cycles
- Valves: Every 5-7 years
- Battery: Every 2-3 years or 1000 cycles
- Controller: Every 5-10 years or on failure
- External Equipment: Every 3-5 years

Bioartificial Kidney:
- Membrane Filters: Every 6-12 months
- Cell Cartridges: Every 1-2 years (if applicable)
- Tubing: Every 3-6 months
- Pumps: Every 2-3 years
- Sensors: Every 1-2 years

3D Bioprinted Skin:
- Replacement: Only if rejection or failure
- Monitoring: Ongoing integration assessment
- Debridement: As needed for wound healing
- Secondary Procedures: Scar revision, etc.
```

---

## 10. Failsafe and Emergency Protocols

### 10.1 Failsafe System Architecture

```
Redundancy Levels:
1. Primary System: Main organ function
2. Backup System: Immediate takeover on failure
3. Emergency Mode: Minimal life-sustaining function
4. Alert System: Notification to patient and medical team
5. External Support: Manual intervention, temporary support

Failsafe Triggers:
- System Failure: Hardware or software malfunction
- Power Loss: Battery depletion, connection loss
- Performance Degradation: Output <50% of target
- Rejection: High rejection risk score
- Patient Command: Manual activation
```

### 10.2 Emergency Response Protocol

```typescript
class EmergencyProtocol {
  activateFailsafe(trigger: FailsafeTrigger): EmergencyResponse {
    // 1. Immediate actions
    this.switchToBackupSystem();
    this.activateAlerts();
    this.logEvent(trigger);

    // 2. Assess situation
    const severity = this.assessSeverity(trigger);
    const timeToFailure = this.estimateTimeToFailure();

    // 3. Determine response
    if (severity === 'CRITICAL') {
      return this.criticalResponse();
    } else if (severity === 'HIGH') {
      return this.highPriorityResponse();
    } else {
      return this.standardResponse();
    }
  }

  criticalResponse(): EmergencyResponse {
    return {
      action: 'IMMEDIATE_MEDICAL_INTERVENTION',
      notification: ['PATIENT', 'EMERGENCY_CONTACT', 'MEDICAL_TEAM', 'EMERGENCY_SERVICES'],
      deviceMode: 'EMERGENCY_MODE',
      instructions: 'Proceed to nearest hospital immediately',
      backupDuration: this.calculateBackupDuration(),
      alternativeSupport: this.identifyAlternatives()
    };
  }
}
```

### 10.3 Backup Power Protocol

```
Power Loss Detection:
- Primary Battery: <10% capacity
- Charging Failure: No charge increase in 30 minutes
- TET Disconnect: Coil misalignment detected
- Power Interruption: Voltage drop below threshold

Automatic Actions:
1. Switch to backup battery (<1 second)
2. Activate low-power mode
3. Alert patient (vibration, sound)
4. Notify medical team
5. Display battery status
6. Disable non-essential functions

Patient Actions:
1. Connect to external power if available
2. Replace/recharge primary battery
3. Realign TET coil if applicable
4. Contact medical team if unable to resolve
5. Proceed to medical facility if critical
```

### 10.4 Rejection Emergency Protocol

```
High Rejection Risk (Score > 0.70):

Immediate Actions:
1. Alert patient and medical team
2. Increase monitoring to continuous
3. Prepare for possible intervention
4. Review immunosuppression protocol
5. Evaluate backup/bridge options

Medical Intervention (Within 24 hours):
1. Physical examination
2. Laboratory tests (comprehensive)
3. Biopsy if indicated
4. Imaging studies
5. Immunosuppression adjustment
6. Consider rescue therapy

Contingency Planning:
1. Bridge device availability
2. Dialysis access (for kidney)
3. ECMO readiness (for heart/lung)
4. Operating room on standby
5. Blood products available
6. Backup organ (if available)
```

---

## 11. Interoperability Standards

### 11.1 Data Exchange Protocol

```json
{
  "protocol": "WIA-AUG-010-DataExchange",
  "version": "1.0",
  "message": {
    "header": {
      "messageId": "MSG-AO-123456",
      "timestamp": "2025-12-27T10:00:00Z",
      "sourceId": "ORGAN-001",
      "destinationId": "MONITOR-001",
      "messageType": "STATUS_UPDATE",
      "priority": "NORMAL"
    },
    "payload": {
      "organType": "HEART",
      "technologyType": "MECHANICAL",
      "status": "ACTIVE",
      "functionMetrics": {
        "output": {
          "value": 5.2,
          "unit": "L/min",
          "target": 5.0,
          "percentOfTarget": 104
        },
        "efficiency": 0.82,
        "power": 1.8
      },
      "biomarkers": {
        "lactate": 1.1,
        "pH": 7.39,
        "pO2": 95
      },
      "alerts": [],
      "batteryLevel": 78
    }
  }
}
```

### 11.2 Standard API

```typescript
interface WIA_AUG_010_API {
  // Classification
  classifyOrgan(input: OrganInput): OrganClassification;

  // Biocompatibility
  assessBiocompatibility(organId: string, data: BiocompatibilityData): BiocompatibilityScore;

  // Function Monitoring
  monitorFunction(organId: string, metrics: FunctionMetrics): MonitoringResult;
  updateBaseline(organId: string, newBaseline: BaselineMetrics): void;

  // Rejection Detection
  detectRejection(organId: string, data: RejectionData): RejectionAssessment;

  // Performance Optimization
  optimizePerformance(organId: string, targets: PerformanceTargets): OptimizationResult;

  // Maintenance
  scheduleService(organId: string): ServiceSchedule;
  predictMaintenance(organId: string): MaintenancePrediction;

  // Emergency
  activateFailsafe(organId: string, mode: FailsafeMode): FailsafeStatus;
  getEmergencyProtocol(organId: string, situation: EmergencySituation): EmergencyResponse;

  // Status
  getStatus(organId: string): OrganStatus;
  getHistory(organId: string, timeRange: TimeRange): HistoricalData;
}
```

### 11.3 Integration with Medical Systems

```
HL7 FHIR Resources:
- Device: Artificial organ device information
- Observation: Function metrics, biomarkers
- Procedure: Implantation, maintenance, interventions
- MedicationRequest: Immunosuppression regimen
- DiagnosticReport: Rejection testing, imaging
- CarePlan: Monitoring schedule, treatment plan

DICOM Integration:
- Imaging: CT, MRI, X-ray for device position
- SR (Structured Reports): Function test results
- Waveforms: Cardiac rhythm, pressure traces

IEEE 11073:
- Medical Device Communication
- Point-of-Care Devices
- Personal Health Devices
```

---

## 12. Implementation Guidelines

### 12.1 Certification Requirements

```
WIA-AUG-010 Certification Checklist:

1. Organ Classification (Section 2)
   □ Complete organ type classification
   □ Technology category selection and justification
   □ Performance target documentation
   □ Safety class determination

2. Biocompatibility (Section 4)
   □ ISO 10993 testing complete
   □ Tissue integration assessment
   □ Immune response monitoring protocol
   □ Material safety documentation

3. Function Monitoring (Section 5)
   □ Real-time monitoring system
   □ Organ-specific metrics defined
   □ Alert threshold configuration
   □ Data logging and reporting

4. Rejection Detection (Section 6)
   □ Immune marker surveillance
   □ Antibody testing protocol
   □ Risk assessment algorithm
   □ Response protocol documented

5. Performance (Section 7)
   □ Optimization algorithm implementation
   □ Efficiency targets met (>70%)
   □ Predictive maintenance system
   □ Long-term stability data

6. Power Systems (Section 8)
   □ Primary power source (>8h)
   □ Backup power system (>30min)
   □ Power management features
   □ Safety certifications

7. Maintenance (Section 9)
   □ Service schedule defined
   □ Component replacement guidelines
   □ Predictive maintenance algorithm
   □ Documentation and training

8. Failsafe (Section 10)
   □ Redundancy systems
   □ Emergency protocols
   □ Backup power failover
   □ Alert and notification system

9. Interoperability (Section 11)
   □ Standard API implementation
   □ Data exchange format compliance
   □ Medical system integration
   □ Security and privacy (HIPAA, GDPR)
```

### 12.2 Performance Benchmarks

```
Minimum Performance Requirements:

Heart (Mechanical):
- Cardiac Output: ≥4.0 L/min (rest), ≥15 L/min (exercise)
- Efficiency: ≥75%
- Durability: ≥5 years MTBF
- Reliability: ≥99% uptime
- Battery Life: ≥12 hours

Kidney (Bioartificial):
- GFR Equivalent: ≥60 ml/min/1.73m²
- Waste Removal: ≥80% of natural kidney
- Electrolyte Balance: Within normal limits
- Durability: ≥3 years
- Biocompatibility: ≥0.80 score

Liver (Bioartificial):
- Detoxification: ≥70% of natural liver
- Synthesis: Albumin ≥3.0 g/dL
- Metabolic Function: ≥70% capacity
- Durability: ≥2 years
- Biocompatibility: ≥0.85 score

Lung (Mechanical):
- Gas Exchange: O₂ ≥250 ml/min, CO₂ ≥200 ml/min
- Efficiency: ≥70%
- Durability: ≥2 years
- Reliability: ≥95% uptime
```

### 12.3 Safety Requirements (per WIA-AUG-013)

```
Safety Class Determination:
- Class I: External, non-invasive (lowest risk)
- Class II: Semi-invasive, temporary (low-moderate risk)
- Class III: Fully invasive, short-term (<30 days) (moderate risk)
- Class IV: Fully invasive, long-term (30 days - 1 year) (high risk)
- Class V: Fully invasive, permanent (>1 year) (highest risk)

Requirements by Class:
Class III-V (Artificial Organs):
- Redundant safety systems
- Continuous monitoring
- Emergency backup (manual or device)
- 24/7 technical support
- Clinical oversight
- Regular safety audits
- Adverse event reporting
- Long-term registry participation
```

---

## 13. References

### 13.1 Related WIA Standards

- WIA-AUG-001: Human Augmentation
- WIA-AUG-013: Augmentation Safety
- WIA-AUG-014: Human-Machine Interface
- WIA-MED: Medical Device Standards
- WIA-BIO: Biocompatibility Standards
- WIA-DATA: Data Exchange Standards
- WIA-SEC: Security and Privacy Standards

### 13.2 International Standards

- ISO 10993: Biological evaluation of medical devices
- ISO 13485: Medical devices — Quality management systems
- ISO 14971: Medical devices — Application of risk management
- IEC 60601: Medical electrical equipment safety
- FDA 21 CFR Part 820: Quality System Regulation
- MDR (EU) 2017/745: Medical Device Regulation

### 13.3 Scientific References

- Griffith, L. G., & Naughton, G. (2002). Tissue engineering—current challenges and expanding opportunities. *Science*, 295(5557), 1009-1014.
- Atala, A. (2009). Engineering organs. *Current Opinion in Biotechnology*, 20(5), 575-592.
- 선행 연구. ISHLT guidelines for artificial organ implantation. *J Heart Lung Transplant*.
- FDA (2023). Guidance for Industry: Artificial Organs and Related Devices.

### 13.4 Clinical Protocols

- UNOS: Organ allocation and transplant protocols
- ISHLT: Heart and lung transplantation guidelines
- AST: American Society of Transplantation guidelines
- Kidney Disease: KDIGO Clinical Practice Guidelines

---

## Appendix A: Organ-Specific Data Sheets

[Detailed specifications for each organ type would be included here]

## Appendix B: Biocompatibility Testing Protocols

[ISO 10993 testing procedures and interpretation]

## Appendix C: Rejection Grading Scales

[Banff classification and organ-specific rejection grading]

## Appendix D: Maintenance Checklists

[Detailed maintenance procedures for each organ type]

## Appendix E: Emergency Response Cards

[Quick reference cards for emergency situations]

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-AUG-010 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
